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INTRODUCTION 
 
 
 
 
 
NON ALCOHOLIC FATTY LIVER DISEASE 
 
DEFINITION 
 
 
The term “non-alcoholic fatty liver disease” (NAFLD) refers to hepatic steatosis accounting for more than 
5% of the total weight of the liver, which is not caused by excessive consumption of alcohol (women ≤20 
g/d, men ≤30 g/d) or hepatotropic viruses. NAFLD is one of the most important chronic liver disorders 
worldwide (1) It covers a wide spectrum of hepatic damage in which simple steatosis (NAFL) can 
progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma 
(HCC) (2). NAFLD is considered to be the hepatic component of metabolic syndrome as its features 
are similar to those of metabolic disorders such as obesity, inflammation, insulin resistance, and type 2 
diabetes (3, 4) Moreover such as metabolic syndrome, NAFLD has been demonstrated to be associated with 
increased risk of cardiovascular diseases (5). 
 
 
EPIDEMIOLOGY 
 
 
In Europe non-alcoholic fatty liver has become the most common cause of chronic liver disease. The 
proportion of NAFLD among chronic liver diseases rose from 47% to 75% between 1988 and 2008. The 
reason for this increase is most probably an increase in metabolic risk factors, also in the context of aging 
populations (6). 
 
In Europe, the prevalence of NAFLD in the population is estimated to be 20% to 30%. A look at special 
subgroups in the population reveals a wide range of the observed prevalence rates—from 2% in unselected 
children to 44% in selected risk groups, such as people with type 2 diabetes, or 90% in obese subjects. No 
reliable data are available on the prevalence of advanced NAFLD and cirrhosis (7). 
 
A strong increase of NAFLD incidence has recently been observed especially in adolescents and in older 
people. The prevalence depends not only on the population under study but also on the study method; the 
differences may be substantial. Studies in potential live liver donors found histologically confirmed NAFLD 
in 20% and 51% of cases, respectively (8). Sonographically the prevalence rate varied between 17% and 
46%, depending on the population under study (7). Worldwide, the assumed prevalence of NAFLD in the 
general population is between 6% and 33%, with a median of 20%; the estimated prevalence of NASH is 
notably lower, at 3% to 5% (9). 
The prevalence of NAFLD is even higher in patients with type 2, but not type 1, diabetes than in the general 
population. An ultrasound based study found a prevalence of 69% among patients with type 2 diabetes (10, 
11). 
Lipid metabolism also seems to have a substantial influence. In many type 2 diabetes patients, raised 
concentrations of triglycerides and lowered concentrations of HDL cholesterol are also observed. In patients 
with dyslipidemia who were attending an outpatient clinic, the prevalence of NAFLD was 50% 
Interestingly, the risk of NAFLD increases independently of the presence of diabetes with each individual 
metabolic risk factor (12). Factors such as age, sex and ethnicity have also been found to play a role: male 
sex, older age, and Hispanic origin are associated with a significantly higher risk of developing NAFLD (9, 
13). 
Patients with NASH are prone to a progressively advanced liver fibrosis and cirrhosis in a rather short time 
(14-16) but there is no specific symptom of NASH that reflect the advanced condition of the patients 
(14,17). 
NAFLD-cirrhosis or NAFLD-Hepatocellular Carcinoma (HCC) are now the second cause of liver 
transplantation in the USA (18) and, as a consequence of the new and effective therapies for chronic viral 
hepatitis, NAFLD-cirrhosis and HCC will become the most common indication for liver transplantation in 
the near future. HCC can also develop in NASH in the absence of cirrhosis (45% of cases) (18). 
 
The risk of progression to end-stage liver disease is influenced by the severity of underlying liver histology; 
the majority of patients with NAFLD have simple steatosis, however, up to 30% of patients may have 
NASH (19) and are at greater risk. Whilst simple steatosis in the absence of significant fibrosis is considered 
to be a relatively benign condition, the presence of fibrosis predicts both disease progression and liver- 
related complications over a subsequent 10-year period. 40% of patients with NAFLD related cirrhosis die 
in 10 years (19). 
 
Several studies with up to 20 years follow-up, have demonstrated that the risk of progression to cirrhosis in 
patients with simple steatosis is between 0% and 4% (20-22). 
 
 
Decreased survival in NASH patients is due predominantly to cardiovascular causes, although there is a 
significant increase in liver-related deaths. NASH also carries an increased risk of hepatocellular carcinoma 
(HCC and thus the observation of increased incidence of HCC in type 2 diabetes is likely to be due to their 
high prevalence of NASH. In US, NASH was found to account for at least 13% of overall cases of HCC (14- 
18-23).
HYSTOLOGICAL   CLASSIFICATION 
 
Figure A: normal liver at histological evaluation. 
 
 
 
Adapted from “Liver and intrahepatic bile ducts - nontumor General  Normal histology” Author: Komal Arora, M.D. Revised: 
15 November 2017, last major update April 2012 Copyright: (c) 2002-2017, PathologyOutlines.com, Inc 
 
 
Figure B: liver steatosis at hystological evaluation. Presence of lipid droplets within hepatocytes. 
Macrovescicular steatosis is characterized by the presence of sa single big lipid droplet (as in the picture). 
Microvescicular steatosis is characterized by the presence of small lipid vesicles. 
 
 
 
Adapted from “Liver and intrahepatic bile ducts - nontumor General Normal histology” Author: Komal Arora, M.D. Revised: 
15 November 2017, last major update April 2012 Copyright: (c) 2002-2017, PathologyOutlines.com, Inc. 
 
 
 
The disorder has a broad histological spectrum from simple NAFL to a progressive hepatic injury condition 
characterized by steatosis-induced inflammation, results from recruitment and activation of inflammatory 
cells in the liver (NASH) (24). 
 
The diagnosis of NASH is established by the presence of a characteristic pattern of steatosis, inflammation 
and hepatocellular ballooning on liver biopsies in the absence of significant alcohol consumption. However, 
diagnostic criteria for NASH. For this reason a scoring system for nonalcoholic fatty liver disease (NAFLD) 
was developed and validated the NAFLD Activity Score (NAS) The methodology proposed for feature-
based scoring of histologic lesions of NAFLD has been widely utilized, as evidenced by its application in 
numerous clinical and experimental settings in NAFLD-related studies. The recognized strengths of the 
method include the relative ease of understanding and therefore, application of the system; division of 
lesions of active and potentially reversible injury (“grade”) in the NAFLD Activity Score (NAS) and those 
potentially less reversible and characterized by collagen deposition and architectural alterations that may 
evolve toward more permanent parenchymal remodeling (“stage”). The proposed NAS also clearly separates 
the three lesions that comprise grade: steatosis, lobular inflammation, and ballooning. This allows detailed 
analysis of histologic changes for comparative and correlative studies in therapeutic intervention trials 
(24). 
 
 
 
 
 
 
 
 
Macrovescicular and microvescicular steatosis 
 
Steatosis in NAFLD is usually seen as macrovesicular steatosis (large droplet steatosis) in which a single, 
large vacuole of fat fills up the hepatocyte and displaces the nucleus to the periphery. Often macrovesicular 
steatosis can be present with both large and small droplets that may be seen to coalesce. Macrovesicular 
steatosis alone is considered to have a good long-term prognosis with rare progression to fibrosis or 
cirrhosis. On the other hand, diffuse microvesicular steatosis denotes a separate clinical entity the diseases 
share severe mitochondrial β-oxidation defects from genetic or acquired causes. Examples include acute 
fatty liver of pregnancy, Reyes syndrome, drugs or toxins (25,26). 
 
These diseases either resolve, or lead to death if not managed with liver transplant. Histologically, 
microvesicular steatosis is characterized by distended hepatocytes with foamy appearing cytoplasm; small 
lipid vesicles (less than 1µm in diameter) may or may not be discernible. The nucleus is typically centrally 
located unlike in macrovesicular steatosis where the nucleus is displaced peripherally. Because of the diffuse 
cytoplasmic alteration, special staining such as oil red O may be required for its diagnosis. Microvesicular 
steatosis is also commonly present in the same hepatocytes that harbor visualizable mitochondria, known as 
“megamitochondria”. Microvesicular steatosis is related to advanced histological features such as 
ballooning, inflammation, steatohepatitis, and fibrosis and is often related to a worse prognosis and 
predisposition to develop liver cirrhosis (27). The worse prognosis of microvescicular steatosis has been 
related to its aetiology (drugs and toxins) and to the presence of inflammation (25, 26), however 
microvescicular steatosis is described also in NAFLD ant its significance is still under debate even it is 
commonly thought to be related to an increased risk of NASH and cirrhosis (27). 
 
 
 
 
 
PYSIOPATHOLOGY 
 
 
Few studies are available on its natural history and although the pathogenesis of NAFLD/NASH is not yet 
fully understood, much progress has been made in recent years in elucidating the mechanisms of progression 
from steatosis to more advanced liver inflammation and fibrosis. 
 
As previously described NAFLD is the accumulation of more than 5% of fat and specifically triglyceride 
within hepatocytes. Triglycerides are formed from the esterification of FFA and glycerol within the 
hepatocyte. FFAs arise in the liver from three distinct sources; lipolysis (the hydrolysis of FFA and glycerol 
from triglyceride) within adipose tissue, dietary sources, and de novo lipogenesis (DNL). In contrast, FFA 
may be utilized either through β-oxidation, re-esterification to triglycerides and storage as lipid droplets, or 
packaged and exported as very low density lipoprotein (VLDL). Hence hepatic fat accumulation can occur 
as a result of increased fat synthesis, increased fat delivery, decreased fat export, and/or decreased fat 
oxidation (28). 
While in healthy subjects <5% of liver triglyceride content derives from DNL, in diabetic patients DNL 
contributes >25% (29). Triglyceride can also be exported from the liver in VLDL particles, which are 
formed by the incorporation of triglyceride into apolipoprotein B (apoB). Aberrant alterations of apoB 
synthesis and secretion have been demonstrated to be involved in the pathogenesis of NAFLD leading to a 
decreased capacity for lipid export (28). 
 
 
 
Some of the mechanisms involved in hepatic triglyceride accumulation are oxidative stress, lipotoxicity, 
mitochondrial damage, insulin resistance, inflammation, and excessive dietary fat intake, which increase 
hepatic lipid influx and de novo lipogenesis and impair insulin signaling. Moreover overproduction of 
proinflammatory adipokines from adipose tissue also affects hepatic metabolic function (19). 
 
At the end of the 90’ the two-hit-hypothesis has been proposed to explain the pathogenesis of NASH (30). 
The first hit is insulin resistance and excessive fatty acids in the circulation, which lead to simple hepatic 
steatosis. The second hit involves oxidative stress, lipid peroxidation, and mitochondrial dysfunction. 
A further component, has been added to reflect inadequate hepatocyte proliferation. In the healthy liver, cell 
death stimulates replication of mature hepatocytes which replace the dead cells and reconstitute normal 
tissue function. Oxidative stress inhibits the replication of mature hepatocytes which results in expansion of 
the hepatic progenitor cell (oval cell). In chronic liver injury, the development of fibrosis/cirrhosis is 
dependent on the efficacy of hepatocyte regeneration, and therefore cell death with impaired proliferation of 
hepatocyte progenitors represents the proposed ‘third hit’ in NAFLD pathogenesis. 
 
With the identification of more advanced mechanisms, NASH was shown to develop through a 
multifactorial better than a consequential process the so called “multiple parallel hits hypothesis”. According 
to this hypothesis a number of different processes such insulin resistance, oxidative stress, inflammation, 
immune system, genetic determinants, nutrition and lifestyle, and changes in the intestinal microbiota (30- 
31) may contribute to liver injury in an overlapped way. 
 
 
 
 
 
The role of insulin resistance and NAFLD 
 
Among these multiple factors, insulin resistance is pivotal for the progression of NAFLD (32). 70%–80% of 
obese and diabetic patients have NAFLD (33, 34). In obese patients with concomitant type 2 diabetes and 
NAFLD, hyperinsulinemia and dyslipidemia are more severe than in patients without NAFLD (35). Insulin 
resistance is related to the excess of circulating FFAs and oxidated FFAs derived from lipogenesis and de 
novo fatty acid synthesis (36). 
 
These FFA either undergo β-oxidation or are esterified with glycerol to form triglycerides, leading to hepatic 
fat accumulation. There is now substantial evidence that FFA can directly cause toxicity by increasing 
oxidative stress and by activation of inflammatory pathways. 
 
Adipose tissue is a mediator of systemic lipid storage but can be considered also an endocrine organ that 
secretes hormones and the group of cytokines known as adipokines, such as adiponectin and leptin (36). 
Adiponectin regulates fatty acid oxidation and inhibits lipid accumulation, both in adipose tissue and in the 
liver (37). It also maintains whole-body glucose homeostasis, including hepatic insulin sensitivity (38). 
Recent studies have shown that serum adiponectin levels are lower in patients with NAFLD (39). 
 
 
 
 
Innate immune system and NAFLD 
 
The innate immune system, also known as the non-specific immune system or in-born immune system (40) 
is an important subsystem of the overall immune system that comprises the cells and mechanisms that 
defend the host from dangerous substances. The cells of the innate system recognize and respond to 
pathogens in a 
  
similar way, but, unlike the adaptive immune system, the system does not provide long-lasting immunity to 
the host (41). 
 
The major components of the innate immune system include inflammatory mediators and specific cells 
activation. The innate leukocytes include: natural killer cells, mast cells, eosinophils, basophils; and the 
phagocytic cells including macrophages, neutrophils, and dendritic cells, and function within the immune 
system by identifying and eliminating pathogens that might cause infection (42) 
Inflammation is one of the first responses of the immune system to infection or irritation. Inflammation is 
stimulated by chemical factors released by injured cells and serves to establish a physical barrier against the 
spread of infection, and to promote healing of any damaged tissue following the clearance of pathogens (43). 
 
The process of acute inflammation is initiated by cells already present in all tissues, mainly resident 
macrophages, dendritic cells, hystiocytes, Kupffer cells, and mastocytes. These cells present receptors contained 
on the surface or within the cell, named pattern recognition receptors (PRRs), which recognize molecules that 
are broadly shared by pathogens but distinguishable from host molecules, collectively referred to as pathogen- 
associated molecular patterns (PAMPs). Chemical factors produced during inflammation (histamine, bradykinin, 
serotonin, leukotrienes, and prostaglandins) sensitize pain receptors, cause local vasodilation of the blood vessels, 
and attract phagocytes, especially neutrophils (43). Neutrophils then trigger other parts of the immune 
system by releasing factors that summon additional leukocytes and lymphocytes. Cytokines produced by 
macrophages and other cells of the innate immune system mediate the inflammatory response. These 
cytokines include TNF, HMGB1, and IL-1(44). 
 
 
 
 
-    Innate immune cells and NAFLD 
 
Overnutrition or insufficient exercise leads to adipose expansion, with the hypertrophic adipocytes secreting 
TNF, IL-1, and IL-6. These pro-inflammatory cytokines down-regulate hepatic insulin sensitivity via the 
activation of pro-inflammatory signaling and the inhibition of insulin receptor signaling. The result is the 
development of liver steatosis and fibrosis (45) 
Immune cells, macrophages/Kupffer cells, natural killer cells, and T-cells contribute to the 
 
progression of NAFLD to NASH. A pivotal role is played by the innate immune system which include 
monucleate circulating cells and inflammatory citokines (46). 
 
 
In particular, hepatic macrophages, which include both resident Kupffer cells and macrophages recruited 
from the peripheral circulation, are the major immune cells that secrete inflammatory mediators, such as 
tumor necrosis factor (TNF)α and interleukin (IL)1β, leading to systemic insulin resistance and NASH (47). 
.T hese cells localize within liver sinusoids, accounting for ~10% of the total number of liver cells (48). 
Macrophages can be classified as M1, or “classically activated” pro-inflammatory macrophages, and M2, or 
“alternatively activated” non-inflammatory macrophages (49–51). Alternative M2 macrophages sustain 
insulin sensitivity via the secretion of anti-inflammatory while classical M1 macrophages secrete pro- 
inflammatory cytokines such as TNFα, IL6, and IL1β, which leads to insulin resistance (50,51). IL-1 is a 
potent inflammatory cytokine mainly produced by macrophages. IL-1 production requires stimulation with 
TLR ligands as well as a second signal. IL-1 participates in toxic, ethanol and NASH-induced fibrosis. In 
HSCs IL-1 mediates upregulation of fibrogenic proteins. Moreover, IL-1 can prolong the survival of HSCs 
(46). 
 
The dysregulation and polarization of M1 and M2 macrophages are closely related to multiple metabolic 
disorders, among them, obesity, insulin resistance, and NAFLD. Hepatic lipid accumulation promoted 
the activation of macrophages/Kupffer cells (52). 
 
 
 
Inflammation in the liver is regulated by the balance of pro-inflammatory M1 Kupffer cells and anti- 
inflammatory M2 Kupffer cells (53). Thus, the exacerbated release of M1 Kupffer-cell-derived mediators 
contributes to the pathogenesis of liver steatosis, the recruitment of inflammatory immune cells, and the 
activation of fibrogenesis (53,54]. Inflammatory cytokines, which in addition to TNF include chemokines 
such as monocyte chemoattractant protein (MCP)-1/C-C chemokine ligand 2 (CCL2) and RANTES/CCL5, 
are produced by M1 cells and increase hepatic lipid accumulation, which results in the discordant regulation 
of lipid metabolism and homeostasis (55). IM2 cells promote the caspase-3-dependent apoptosis of 
classically activated M1 cells and thus provide a protective mechanism against NAFLD (54). Because the 
M1/M2 ratio is increased during NAFLD progression, the polarization of cells into M2 Kupffer cells might 
be an important mechanism protecting against fatty liver disease (46). 
 
 
 
- Inflammatory signaling and chemokine production in NAFLD 
 
The presence of steatosis is tightly associated with chronic hepatic inflammation (56) an effect in part 
mediated by activation of the Iκκ-β/NF-κB signalling pathway. In murine models of high-fat diet (HFD)- 
induced steatosis, increased NF-κB activity is associated with elevated hepatic expression of inflammatory 
cytokines such as TNF-α, interleukin-6 (IL-6) and interleukin 1-beta (IL-1β), and activation of Kupffer cells 
(56). 
 
Liver-specific NF-κB inhibition prevents HFD-induced inflammatory gene expression, whereas HFD- 
induced hyperglycaemia and IR can be reproduced by selective over-expression of constitutively active Iκκ- 
β in hepatocytes (56) The Iκκ-β/NF-κB pathway in hepatocytes can also be activated directly by FFA, 
providing a further mechanism by which central obesity with consequent increased hepatic FFA supply can 
contribute to inflammation (57, 58). 
 
Both serum and hepatic levels of TNF-α are elevated in patients with NASH (54) and levels correlate with 
histological severity (55) In addition to its proinflammatory effects, TNF-α promotes IR. Conversely, 
inhibition of TNF-α signalling improves IR and histological parameters of NASH (59-61). Similarly, serum 
IL-6 levels are also elevated in both animal and human models of IR and NAFLD (62, 63) and levels 
correlate with increasing liver inflammation and fibrosis (64) The key role of hepatocyte cytokine 
production in the progression of steatosis to NASH is supported by studies demonstrating that cytokines can 
replicate all of the histological features associated with NASH, including neutrophil chemotaxis, hepatocyte 
apoptosis/necrosis, Mallory body formation and stellate cell activation (65) Additionally, data suggests that 
inflammation and NF-κB activation can promote carcinogenesis(66) and that the chronic inflammatory state 
associated with hepatic steatosis may also play a key role in HCC development (65). 
 
 
 
Chemokines are a family of cytokines that activate leukocyte chemotaxis and play important roles in the 
progression of systemic inflammation (59,67). By recruiting immune cells to adipose tissue, liver, and 
skeletal muscle, chemokines lead to acute inflammation and the development of insulin resistance, as well as 
fatty liver disease (60-62). The chemokine (C-C motif) ligand 2 (CCL2) is a small cytokine primarily 
secreted by monocytes, macrophages and dendritic cells CCL2 recruits monocytes, memory T cells, and dendritic 
cells to the sites of inflammation. CCL2 impairs insulin signaling in skeletal muscle significantly reduced 
insulin-stimulated glucose uptake in myocytes. CCL2, is up-regulated in obese adipose tissue, secondary to 
macrophage infiltration (63, 64). By binding to the CCR2 receptor, CCL2 causes the infiltration of bone 
marrow-derived macrophages into obese adipose tissue or liver. It is also involved in the development of 
hepatic steatosis and insulin resistance (62-64). Recent studies show how the CCL2/CCLR axis plays a 
central role in murine model of obesity-induced liver disease. The specific overexpression of CCL2 in the 
adipose tissue of mice leads to the development of insulin resistance, inflammation, and hepatic steatosis 
(66). Conversely, mice with a genetic deletion of CCR2 have improved insulin sensitivity and inflammation, 
without a decrease in body weight, in agreement with the findings obtained with pharmacological 
antagonists of CCR2 (63, 68). However, there are also studies reporting conflicting results, showing that 
MCP-1-deficient mice do not exhibit reduced macrophage infiltration or improved insulin sensitivity, which 
suggests that CCL2-CCR2 signaling is not critical for obesity-induced macrophage recruitment or systemic 
insulin resistance (69, 70). 
 
 
The hepatic infiltration of macrophages/Kupffer cells is primarily promoted by CCL2, as these cells express 
CCR2 (71). CCL2 expression in hepatocytes is increased in animals fed a high-fat diet and leads to the 
hepatic recruitment of CCR2+ myeloid cells that promote hepatic steatosis (62). 
 
 
The CCL2-CCR2 pathway is also up-regulated in the livers of animals with NASH and is critical to the 
development of hepatic steatosis and fibrosis by promoting the activation and migration of hepatic stellate 
cells (72) Serum and liver CCL2 levels are increased in NASH patients (71), whereas in animal NASH 
models, the genetic deletion of CCL2 and CCR2 or the inactivation of CCR2 reduces macrophage 
infiltration, attenuates obesity, and improves both insulin resistance and hepatic 
steatosis (63, 64, 72). Thus, collectively, CCL2-CCR2 signaling is central to the progression of hepatic 
steatosis to NASH. 
 
 
 
- The Inflammasome 
 
 
The inflammasome is a multiprotein oligomer responsible for the activation of inflammatory responses 
(73). It is expressed in myeloid cells and is a component of the innate immune system. The inflammasome 
promotes the maturation and secretion of pro-inflammatory cytokines IL-1β and IL-18. 
 
During an infection, one of the first forms of defense employed by the innate immune response is a group of 
pattern recognition receptors (PRRs) encoded in the germline to recognize molecular patterns expressed 
by invading pathogens. These may either be on the membrane surface e.g. Toll-like receptors (TLRs) and 
C- type Lectin Receptor  (CLRs) or inside  the cytoplasm e.g. Nod-like receptors (NLRs)  and RIG-I-
like receptors (RLRs). In 2002, it was first reported by Martinon et al. that a subset of NLRs named NLRP1 
were able to assemble and oligomerize into a common structure which collectively activated the 
caspase-1 cascade, thereby leading to the production of pro-inflammatory cytokines especially IL-1B and 
IL-18. This NLRP1 multi-molecular complex was dubbed the ‘inflammasome’, which spurred much 
interest in the following years; since then, several other inflammasomes were discovered, two of which 
are also NLR subsets—NLRP3 and NLRC4 (74). One of the most recently identified contributor to the 
cross talk between hepatocytes and inflammatory macrophages is represented by the multiprotein platform 
complex nucleotide- binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome, 
whose activation has been suggested to play a crucial role in the progression of NAFLD (75) 
 
In particular, the transition from NAFLD to NASH associates with NLRP3-inflammasome activation and an 
increased expression of inflammasome-related components, including apoptosis-associated speck-like 
protein containing a carboxy-terminal CARD (ASC), caspase-1 (CASP-1) and pannexin (76-79). 
In addition, inflammasome activation involves not only liver innate immunity cells but also parenchymal 
cells (78, 79) with studies indicating that saturated fatty acids can specifically activate the inflammasome 
complex in hepatocytes inducing IL-1β expression and release (75, 79). However, no study has so far 
investigated whether MVs released from fat-laden hepatocytes may promote NLRP3-inflammasome 
activation (75). 
FIGURE C: Schematic representation of the the progression of NAFLD/NASH: Excess fat intake and 
obesity lead to hyperglycemia, hyperlipidemia, and the oversecretion of adipocytokines and chemokines 
such as tumor necrosis factor (TNF), interleukin (IL)-1 β, and monocyte chemoattractant protein (MCP)- 
1/C-C chemokine ligand 2 (CCL2). These factors further contribute to the development of systemic insulin 
resistance and hepatic steatosis. The latter causes hepatic inflammation and induces NASH and even 
cirrhosis. Hepatic inflammation involves the recruitment of macrophages/Kupffer cells and an M1-dominant 
phenotypic shift in macrophages in the liver, activating hepatic stellate cells and finally leading to liver 
fibrosis. 
 
 
 
 
 
Adapted from “Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and 
Potential New Treatments. Nutrients. 2017 Apr; 9(4): 387” 
CLINICAL PRESENTATION AND DIAGNOSTIC EVALUATION 
 
The findings in NAFLD tend to be non-specific. Most patients have no symptoms or signs of hepatic disease 
at the time of diagnosis. 
In terms of laboratory chemistry, pathological values of aspartate-aminotransferase [AST] and alanine- 
aminotransferase [ALT] may be noted (12) 
However, even normal levels for transaminases do not rule out NASH, and raised concentrations are partly 
re-normalized when cirrhosis develops. The ferritin concentration is raised in about half of patients, and 
transferrin saturation increased in 6–11%. The liver’s iron content is typically within the normal range (12). 
Furthermore, commercial combined tests and apoptosis markers (cytokeratine-18 fragments) (80) are 
available however, these have not gained any importance in routine clinical practice (6 ) 
 
 
A recently proposed diagnostic tool for NAFLD evaluation is the determination of Lysosomal acid lipase 
(LAL) activity on dried blood spots (81). 
Lysosomal acid lipase (LAL) is a key enzyme in lipid metabolism. LAL Deficiency (is an autosomal 
recessive disorder caused by a deficiency of the enzyme. It can manifest as a severe infantile and rapidly 
progressive disorder, Wolman’s disease, or the more attenuated form which manifests in childhood or 
adolescence as a progressive disease. The natural history and the clinical manifestations of the disease in 
children and adults are less well defined and the diagnosis is often incidental. Lipid abnormalities are 
common, and patients may present early signs of systemic atherosclerosis. Moreover, hepatomegaly and 
microvescicular steatosis with liver cell damage and splenomegaly are common features of the disease (81). 
 
LAL is a key enzyme involved in intracellular lipid metabolism and trafficking; it is responsible for the 
intra-lysosomal hydrolysis of LDL CE and triglycerides into free cholesterol and free fatty acids (82). 
Therefore, the reduction of LAL activity determines intra-lysosomal lipid accumulation and a consecutive 
reduction of free cholesterol in cytosol 
 
LAL activity reduction should always be suspected in non-obese patients presenting with NAFLD and/or 
cryptogenic cirrhosis, unexplained persistently elevated liver transaminases or with elevation in LDL-C and 
decreased HDL-C. 
 
In vitro, it has been demonstrated that several factors may modulate LAL activity (83). 
 
 
In particular, enhanced LAL activity was associated with eicosanoids, gonadotropins and glucagon, and 
reduced activity was correlated with Lp(a), LDL remnants and oxidized LDL concentrations. 
 
Initial reports have suggested a role for a relative acquired LAL deficiency in non-alcoholic fatty liver 
disease (NAFLD)-however, it is still unclear whether this mechanism is specific for NAFLD. Baratta et al. 
in 2015 reported for the first time reduced blood LAL activity in adult patients with NAFLD (84, 85). 
Tovoli et al recently demonstrated that LAL activity is significantly reduced in NAFLD as compared to that 
in HCV patients. In their study this finding was particularly evident in the pre-cirrhotic stage of disease. 
LAL activity was also correlated with platelet and white blood cell count, suggesting an analytic interference 
of portal-hypertension-induced pancytopenia on dried blood spots -determined LAL activity (86). 
 
 
 
 
 
Despite the potential usefulness of the described biochemical tests, liver biopsy is still the gold standard in 
the diagnostic evaluation of NAFLD, because NASH can be formally diagnosed only by means of 
histological testing. However, liver biopsy is an invasive procedure, which carries a risk of potentially life 
threatening complications (6). Moreover there is evidence that NASH is erroneously not identified in up to 
one-third of patients, and that the degree of fibrosis may be subject to overestimation as well as 
underestimation (87) 
Since patients are usually asymptomatic and the laboratory parameters often normal, the question in routine 
clinical practice is which patients should be investigated for NAFLD. A practical recommendation is 
urgently needed in this setting. The current US NAFLD guideline advises against general NAFLD screening 
at this time, owing to the lack of evidence of benefit and the relatively high cost, not even in high-risk 
groups such as obese patients or patients with diabetes (88). In Germany, the clinical practice guideline on 
the diagnosis and treatment of hepatocellular carcinoma recommends a general ultrasound follow-up not 
only in cirrhosis but also in patients with NASH (89) In principle this requires a liver biopsy in all patients 
with a fatty liver, in order to identify high-risk patients with NASH or higher-grade fibrosis. To date, no 
clear guidance is given in the literature with regard to defining an indication for liver biopsy in NAFLD 
 
 
The non-invasive method that is certainly most suitable for detecting hepatic steatosis is ultrasound 
(sensitivity 60–94%, specificity 66–97%), but this is rather less precise in milder degrees of steatosis (90) 
According to available study data, the positive predictive value in mild steatosis is only 67% at best (90). 
Outside the study setting, the positive predictive value is likely to be even lower. The degree of hepatic 
fibrosis can now be estimated non-invasively by using several techniques of elastography (including 
FibroScan and acoustic radiation force impulse imaging [ARFI]) (91). The FibroScan investigation enables 
distinction between fibrosis (F1–F3) and cirrhosis (92), but in morbid obesity it is not equal to the task. 
 
For routine clinical practice, the question remains how high-risk patients can be identified. Recently, a 
number of simple clinical risk scores has shown excellent consistency with the degree of fibrosis in patients 
with steatosis (93). The best result was seen for the NAFLD fibrosis score (http://nafldscore.com), which 
consists of the parameters age, BMI, diabetes, AST, ALT, thrombocytes, and albumin (positive predictive 
value 82–90%, negative predictive value 88–93%). An increased risk of higher-degree fibrosis was 
described for patients with a BMI >32 kg/m2, age >45 years, diabetes, and a ratio of ALT/AST>1 (94). New 
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genetic markers, such as variants of PNPLA3 (adiponutrin), which indicate an increased risk of progression 
towards NASH, fibrosis, and HCC, have not yet become established in routine clinical practice (95, 96) 
 
In combination with findings from sonography or elastography, these clinical scores can help identify 
patients for diagnostic liver biopsy or close clinical and sonographic monitoring of the clinical course (six- 
monthly in NASH). The high coincidence of type 2 diabetes and NAFLD justifies routine diabetes screening 
(HbA1c and oral glucose tolerance test, if required) (6). 
 
 
 
 
US and Doppler evaluation in NAFLD 
 
 
US is a non-invasive, extremely safe, widely available, and inexpensive method used for detecting fatty 
liver and assessing the stages of NAFLD (97,98). The bright liver, consisting of hyperechogenic liver tissue 
with fine, tightly packed echoes at US examination, is considered characteristic for fatty liver (99, 100). 
Studies have documented a sensitivity of 82-89% and a specificity of 93% for B-mode US to identify liver 
fatty infiltration (100). 
 
US can both estimate the degree of fatty infiltration on gray scale mode and evaluate its effect on the hepatic 
vascular system through spectral Doppler analysis . 
 
 
On the basis of the gray scale intensity, our group in Padova developed a quantitative classification. The  
degree of steatosis is defined by the comparative analysis of grey intensity measured on digital sonographic 
images of the liver and right kidney. Briefly, US images of both organs were acquired with an ATL 5000 
scanner (ATL Ultrasound, City), transferred to a personal computer, and analyzed with dedicated software 
(HDI-Lab) (11, unpublished data, J Hepatol 2008, abstract 921) The grey-scale intensity of selected regions of 
interest was measured, and a liver/ kidney (L/K) ratio was calculated, which has been shown to display direct 
correlation with the degree of steatosis measured by histology. 
 
FIGURE D: sonographic evaluation of L/K ratio (adapted from Gaiani et al J Hepatol 2008, abstract 921) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L/K=1.26 
Portal vein blood flow velocity is reduced in patients with fatty liver when compared to the controls and it 
also correlated with the severity of the fatty liver. 
 
 
 
Erdogmus B et al., and Balci et al., and most of the others emphasizes the hypothesis that the fatty 
infiltration of the liver causes increased resistance to the flow of portal vein thereby reducing the portal 
blood flow to the liver (104-108). 
However, the relative contribution of intrahepatic fat deposition to the hepatic vessels’ flow pattern 
alterations is still controversial (105, 109). 
 
Diffuse fatty infiltration of the liver can alter the also hemodynamics in the hepatic veins as well as the 
hepatic artery (101, 102). 
 
Recent studies have evaluated hepatic vessel flow abnormalities as an indicator for early diagnosis of fatty 
liver, and reported a decrease in hepatic artery resistance indexes (RI) in Doppler US in patients (110-112). 
The resistance in vascular bed can be measured by Doppler indexes such as RI and PI, which are widely 
used to evaluate arterial vascular resistance and compare systolic and diastolic flow. The normal hepatic 
arterial system has low resistance flow characteristics reported at 0.60-0.70 in fasting healthy subjects. 
However, there are not large-scale studies assessing hepatic artery RI so far (113). 
 
According to Mihmanli et al. RI decreases gradually as severity of fatty infiltration increases (97). In 
another study performed in Iran, hepatic artery RI also decreased in subjects with fatty liver (100). 
Balasubramanian et al found a better correlation of hepatic artery PI than portal  vein f low velocity 
(PVV) with the grading of the severity of NAFLD (114). 
Recent studies have documented that waveform pattern of portal vein and PI index may also change in 
subjects with fatty liver (104,109), whereas a criterion for response to therapy is still under debate (97, 98) 
 
In summary, Doppler indexes including hepatic artery RI might contribute to evaluating treatment efficacy 
on NAFLD, and might show improvement in NAFLD patients during the course of therapy, which helps 
to prevent unnecessary health care costs by negating the need for further diagnostic tests and 
interventions (115) 
TREATMENTS 
 
 
Despite an increasing understanding of the mechanisms of NAFLD pathogenesis, there is not well established 
therapy for the disease. Current treatments are primarily directed towards improving the metabolic parameters 
which contribute to disease pathogenesis, such as weight loss and exercise, reducing IR and improving diabetic 
control. 
Therapeutic options in NAFLD and NASH are currently limited mainly to interventions in terms of diet and 
lifestyle In addition to lifestyle changes, current therapies utilized for patients with NAFLD include insulin 
sensitizers, e.g. metformin and the thiazolidinediones, vitamin E and consideration of bariatric surgery for 
morbidly obese patients. In recent years, different  drug based approaches  have been investigated in 
randomized, placebo controlled studies. 
 
When such measures fail, liver transplantation remains the only option for patients with end-stage cirrhosis 
(28). 
 
A medication with long-term effectiveness that would beneficially affect the course of fibrosis does 
currently does not exist. 
 
Diet and lifestyle 
 
 
The most effective treatment consists of weight reduction and intensive lifestyle modification with an 
increase in physical activity/exercise, which has been confirmed to be able to improve histological results 
(88). 
 
In a randomized controlled trial, an increase in physical activity of moderate intensity to some 200 minutes 
per week resulted in weight loss of 9% and significant improvements of steatosis and necroinflammation on 
hepatic histology over 48 weeks (116). In general, a reduction in weight of at least 3–5% seems required to 
positively affect the steatosis; with regard to necroinflammation, a weight loss of at least 9% is required (88) 
 
Metformin 
 
 
Several studies investigated the effect of metformin on aminotransferases and liver histology in patients with 
NASH. Early small, open‐label, studies demonstrated a reduction in insulin resistance and aminotransferases 
but no significant improvement in liver histology (117, 118). 
Aminotransferases improved more with metformin than with vitamin E or diet alone. However, there was 
only a modest improvement in hepatic steatosis and inflammation. 
However, a recent meta-analysis has shown that treatment  with  metformin  for  6–12  months,  combined  
with  a  lifestyle  intervention,  does  not  improve neither transaminases nor liver histology compared with a 
lifestyle intervention alone (9). Another meta-analysis and a case–control study in combination with an in-
vitro study indicated, however, that metformin may have a positive effect in terms of the incidence of HCC 
(6). However, according to AASLD guideline, Metformin has no significant effect on liver histology and is 
not recommended as a specific treatment for liver disease in adults with NASH. (Strength – 1, Evidence ‐ A 
(14) 
Thiazolidinediones 
 
 
Thiazolidinediones or TZDs act by activating peroxisome proliferator-activated receptors (PPARs), PPARs 
are free fatty acids-activated transcription factors and belong to the nuclear receptor superfamily. PPARs 
regulate transcription of target genes. The 3 PPAR isotypes, PPARα, PPARγ, and PPARδ play a key role in 
the regulation of lipid and glucose metabolism (119,120). 
 
Targeting PPAR isotypes for the treatment of fatty liver disease has been extensively studied, mainly in the 
case of PPARα However, although the beneficial effect of activating PPARα for NAFLD has been proven in 
several mouse models fibrates, which are PPARα agonists, do not correct NAFLD in humans (120, 14) 
 
Pioglitazone and Rosiglitazone are ligands for the transcription factor (PPAR) γ (119) 
 
The endogenous ligands for these receptors are free fatty acids (FFAs) and eicosanoids. When activated, the 
receptor binds to DNA in complex with the retinoid X receptor (RXR), another nuclear receptor, increasing 
transcription of a number of specific genes and decreasing transcription of others. The main effect of 
expression and repression of specific genes is an increase in the storage of fatty acids in adipocytes, thereby 
decreasing the amount of fatty acids present in circulation. As a result, cells become more dependent on the 
oxidation of carbohydrates, more specifically glucose, in order to yield energy for other cellular processes. By 
this mechanism TZDs are able to improve both hepatic and peripheral insulin sensitivity (119-121). 
 
Several studies investigated the effect of TZDs on NAFLD and NASH. Pioglitazone seems to have a 
positive effect, which in several studies improved the steatosis as well as the inflammation (122) In an an 
early uncontrolled open label study (123) in 22 subjects with biopsy‐proven NASH, rosiglitazone improved 
aminotransferases and hepatic steatosis, ballooning and inflammation scores, but not fibrosis.. This result is 
 
confirmed by a meta analysis (9, which. showed that pioglitazone significantly improves steatosis and 
inflammation, but not fibrosis. 
 
Data on the long-term effects and safety are lacking (9, 88). Moreover, due to increased risk of coronary 
events, rosiglitazone is no longer marketed in Europe and its use is highly restricted in the United States. 
according  to  AASLD  guideline  Pioglitazone  can  be  used  to  treat  steatohepatitis  in  patients  with 
biopsy‐proven NASH. However, it should be noted that majority of the patients who participated in clinical 
trials that investigated pioglitazone for NASH were non‐diabetic and that long term safety and efficacy of 
pioglitazone in patients with NASH is not established. (Strength – 1, Evidence ‐ B) (14). 
 
Vitamin E 
 
 
Oxidative stress is considered to be a key mechanism of hepatocellular injury and disease progression in 
subjects with NASH. Vitamin E is an anti‐oxidant and has been investigated to treat NASH (124) The use of 
vitamin  E  is  associated  with  a  decrease  in  aminotransferases  in  subjects  with  NASH,  studies  where 
 
histologic endpoints were evaluated indicate that vitamin E causes improvement in steatosis, inflammation, 
and ballooning and resolution of steatohepatitis in adults with NASH, and vitamin E has no effect on hepatic 
fibrosis. 
 
In the randomized, placebo controlled PIVENS study in non-diabetic patients, vitamin E lowered 
transaminases and histologically improved steatosis and inflammation after two years of treatment, but did 
not affect the degree of fibrosis (125- 127) One concern with vitamin E is the controversial issue of whether 
it increases all‐cause mortality. Some meta‐analyses have reported an increase in all‐cause mortality with 
high dose vitamin E (128) but others failed to confirm such an association (129). The US guideline therefore 
does not recommend vitamin E in non-diabetic patients with histologically confirmed NASH, but it does 
recommend against its use in diabetes patients, in the absence of histological results, and in case of NASH 
cirrhosis or cryptogenic cirrhosis, until robust data are available (88) 
 
Other treatmens: PUFAs, such as omega-3 and omega-6 fatty acids, are therapeutic targets for CVD and 
metabolic disorders because they can regulate inflammation. PUFAs are essential fatty acids; they are only 
available from dietary sources. Their regulatory role in inflammation was first identified when high dietary 
PUFA intake was correlated with low risk for CVD in humans. They have been proposed as therapeutic 
compound for NAFLD, initial reports demonstrate their effectiveness and large clinical studies are actually 
ongoing (130) 
 
Bariatric Surgery 
 
 
As the majority of patients undergoing bariatric surgery have associated fatty liver disease, there has been an 
interest in foregut bariatric surgery as a potential treatment option for NASH. There are no RCTs that 
evaluated any type of foregut bariatric surgical procedure to specifically treat NAFLD or NASH. However, 
there are several retrospective and prospective cohort studies The study by Mathurin et al.(131) 
prospectively correlated clinical and metabolic data with liver histology before and 1 and 5 years after 
bariatric surgery in 381 adult patients with severe obesity. Compared to baseline, there was a significant 
improvement in the prevalence and severity of steatosis and ballooning at 1 and 5 years following bariatric 
surgery. Two meta‐analyses (132, 133) evaluated the effect of bariatric surgery on the liver histology in 
patients with NAFLD. The meta‐analysis by Mummadi et al., (132) showed that steatosis, steatohepatitis, 
and fibrosis appear to improve or completely resolve after bariatric surgery. However, a Cochrane review 
(133) concluded that lack of randomized clinical trials or quasi‐randomized clinical studies prevents 
definitive assessment of benefits and harms of bariatric surgery as a therapeutic approach for patients with 
NASH. 
 
 
 
New potentially therapeuthic compounds: 
 
 
As no one of the described compounds meets the ideal characteristics of a specific drug for NAFLD the 
urgent need for specific treatments for NAFLD has rendered this a critical area of research, with particular 
focus on developing treatments which can reverse or prevent the more advanced and clinically relevant 
stages of  NASH. 
 
The main phisyopathological targets for NAFLD therapies are lipid metabolism and insulin sensitivity but 
also inflammation and in particular early inflammatory mediators that can be involved in the early phases of 
NAFL evolution to NASH. 
 
 
 
 
 
ANIMAL MODELS OF NAFLD 
 
An ideal animal model of NAFLD/NASH should reflect hepatic histopathology and pathophysiology of 
human NAFLD/NASH. Accordingly, the liver  of the animal model of NASH should show steatosis, 
intralobular inflammation, hepatocellular ballooning, and, ideally, perisinusoidal fibrosis in zone 3 and 
susceptibility to liver tumors. Furthermore, the animal should show metabolic abnormalities such as obesity, 
insulin resistance, fasting hyperglycemia, dyslipidemia, and altered adipokine profile. It is questionable 
whether the results of a study using an animal model that does not completely fulfill these 
conditions can be extrapolated to human disease. Animal models of NAFLD/NASH are classified into 
genetic models, nutritional models, and combination models of genetic and nutritional factors (134) 
 
 
Rodents genetic models refers almost exclusively to mice. Mice are easily to be genetically manipulated but 
due to their small size the amount of blood and tissues from each animal is restrained, moreover the 
phisiophatology of the disease is often invalidated by the lack or the overexpression of key proteins. 
The most commonly used transgenic mice models of NAFLD are: 
 
- SREBP-1c transgenic mice In the fat tissue of these mice, SREBP-1c, a lipogenic transcription 
factor, is overexpressed. This creates a model of congenital lipodystrophy in which severe insulin 
resistance and diabetes develop secondary to impaired adipose differentiation (135). 
- Ob/ob mice Ob/ob mice possess a spontaneous mutation in the leptin gene (leptin-deficient). Leptin 
is an adipokine produced by white adipose tissue and operates on the hypothalamic ventral median 
nucleus exerting a marked anorexic effect (136) 
- Db/db mice Db/db mice possess a natural mutation in the leptin receptor (Ob-Rb) gene (137) and, 
therefore, show normal or elevated levels of leptin but are resistant to the effects of leptin. 
 
 
On the other hand dietary models of NAFLD can be applied both to mice and rats. The most commonly used 
models of dietary induced NAFLD are: 
- Methionine and choline deficiency (MCD) The MCD diet contains high sucrose and fat (40% 
sucrose, 10% fat) but lacks methionine and choline, which are essential for hepatic β-oxidation and 
production of VLDL (136). In addition, choline deficiency impairs hepatic VLDL secretion (138). 
As a result, lipid is deposited in the liver. Furthermore, oxidative stress (139, 140) and changes in 
cytokines and adipocytokines (141) occur, contributing to the liver injury. Steatohepatitis occurs at 
day 10 (142, 143), and perisinusoidal fibrosis is observed by 8-10 wk in mice (139, 143) 
- HF diet Lieber et al (144) reported a diet model of NASH by using an HF diet (71% of energy from 
fat, 11% from carbohydrates, and 18% from proteins). Rats fed this diet ad libitum for 3 wk showed 
elevated plasma insulin levels reflecting insulin resistance. Rats fed the HF diet developed marked 
panlobular steatosis, and the hepatic lipid concentrations of these rats were approximately twice 
those of control rats fed the standard Lieber-DeCarli diet (35% fat, 47% carbohydrates, and 18% 
protein). Like human NASH, the rats fed the HF diet developed oxidative damage in the liver. An 
HF diet is widely used to cause hepatic steatosis and NASH in experimental animals. It is probably 
the model that better reproduces the physiopathology of human NAFLD. However, it seems that the 
HF diet  model produces variable results with regard to the degree of steatosis, inflammation, and 
fibrosis,  and the  results  depend  on  rodent  species  and  strain,  the  fat  content  in  the  diet,  the 
composition of dietary fat,and the duration of treatment. On the other hand, it was reported that long 
term high saturated fat feeding did not induce hepatic steatosis and NASH in Wistar rats (145). 
- Cholesterol and cholate Matsuzawa et al (146) fed mice an atherogenic diet containing 1.25% 
cholesterol and 0.5% cholate and observed the progressive formation of steatosis, inflammation, and 
fibrosis in a time-dependent manner over 6-24 wk. In the model, hepatocellular ballooning, 
characteristic of human NASH, was observed at 24 wk. When 60% fat (cocoa butter) was added to 
the  diet, development of  these  histopathological  features  was  accelerated,  and  hepatocellular 
ballooning was observed at 12 wk. Furthermore, the atherogenic diet induced oxidative stress. Thus, 
it is  conceivable that a combination diet of HF, cholesterol, and cholate in animals would cause 
histological features reminiscent of human NASH. However, the mice fed this diet were 
systematically insulin sensitive, albeit they showed hepatic insulin resistance. In fact, the mice lost 
9% body weight during the experiment and low plasma triglyceride levels compared with those in 
control mice. Therefore, this model appears to differ from human NASH in metabolic status. 
- Fructose Experimental animals fed a fructose enriched diet are recognized  as  good  models  of 
metabolic syndrome. Wistar rats fed a highfructose (70%) diet for 5 wk develop significantly higher 
macrovesicular steatosis and intralobular inflammation grades, liver:body weight ratios, and hepatic 
triglyceride concentrations than those in control rats (147). Rats fed a high-fructose diet show 
significantly higher expressions of interleukin (IL)-6 protein and TNF-α protein in the liver 
compared with those in control rats Armutcu et al (148) reported that male Wistar albino rats 
provided with drinking water containing 10% fructose for 10 d developed macrovesicular and 
microvesicular steatosis but did not develop inflammation in the liver. 
AIMS 
 
 
As described in the introduction NAFLD is a worldwide increasing disease but still many questions about 
its evolution the need of a screening and the availability of effective specific treatments are open. 
 
Aims of my PhD project were 
 
 
1) the evaluation of NAFLD natural history in a subgroup of NAFLD affected diabetic patients enrolled 
during the daily clinical activity of our splenohepatology ecoDoppler laboratory (DIMED, university 
of Padova) in order to identify, if present, predictive factors of “evolutive NAFLD”; 
 
2) the experimental evaluation, in HFD fed rats, of the potential therapeutic effect of 3 molecules 
targeting respectively: 
 
 
a) lipid metabolism (Apolipoprotein A analogue compound -L4F), 
 
 
b) insulin sensitivity (peroxisome proliferator activated receptor delta agonist –PPARd agonist) 
 
 
c) endothelial function (EET Analog). 
 
 
 
We developed two studies: a clinical observational study and an experimental study. 
CLINICAL STUDY: NATURAL HISTORY OF NAFLD IN TYPE 2 NON OBESE DIABETIC 
PATIENTS: A 6 YEARS FOLLOW UP 
 
Thirty % of adults and 70-90% of diabetic patients have NAFLD. (13). The disorder has a broad 
histological spectrum from simple fatty liver (NAFL) to a progressive hepatic injury condition, called 
non-alcoholic steatohepatitis NASH. Those who suffer of NASH are prone to a progressively advanced 
liver fibrosis and cirrhosis in a rather short time (14, 16). 
 
Though histopathology is still considered the gold standard for the diagnosis of NAFLD, it is not possible in 
clinical practice to do biopsy in the huge population of NAFLD patients, considering its invasiveness. 
Hence, imaging modalities such as sonography are now considered a reasonable and acceptable option for 
diagnosing NAFLD (149) 
Recent reports suggest that NAFL may not be as benign as previously thought, with evidence of progression 
to advanced fibrosis, challenging the idea that the risk of fibrosis progression is dichotomized according to 
the presence or absence of NASH (12, 16, 150). Moreover Wong et al. (151) reported in a prospective study 
of paired liver biopsies taken a median three years apart, that 28% of patients with histological NAFLD 
activity score (NAS) <3 (i.e., non-NASH) had fibrosis progression at three years. This confirms the idea that 
histological evaluation is not sufficient to identify among patients with NAFLD those who will develop 
NASH. 
 
Collectively histological prospective and retrospective studies (1-3, 5-7, 9-12) suggest that overall NAFL 
has a more indolent rate of progression than NASH; however, there is considerable heterogeneity, with one 
quarter of NAFL patients developing bridging fibrosis over a relatively short time period. Currently, reliable 
histological and clinical predictors of disease progression are lacking. The majority of studies on NAFLD 
focus on which are the main factors that influence fibrosis development in NASH, in fact fibrosis 
development is considered the pathogenic step that leds from NASH to cirrhosis (28-30). 
 
Few studies focus on the causative element of NAFL progression to NASH (28) and fibrosis although the 
early identification of patients with NAFL who are at higher risk of NASH development could be the real 
preventive goal of NAFLD related cirrhosis development. 
 
Aims of this study were the evaluation of NAFLD “natural history” in non-obese diabetic patients without 
any specific intervention and the identification of non-invasive early markers of potentially evolutive 
disease. 
 
We chose this specific subpopulation of NAFLD patients because of the high prevalence of disease and to 
reduce aetiology variability. Moreover a recent study demonstrated that although patients with non obese 
NAFLD have lower stages of fibrosis, they are at higher risk for development of severe liver disease 
compared to patients with NAFLD and a higher BMI (152). 
Design of the study and materials and methods:  
 
 
100 patients with type 2 diabetes (60 male and 40 female) were evaluated as far as steatosis is concerned. 
Among them, 80 had sonographic signs of steatosis. There was no difference in the prevalence between 
male and female patients. Twenty-one type 2 diabetic patients with liver steatosis were reevaluated after 6 
years. 
 
These 21 patients were our study population as we had basal and “after 6 years” data for each patient. 
 
 
All patients signed an informed consent according to our Ethical Committee indication. According to 
AASLD guidelines (153) the diagnosis of NAFLD requires that (a) there is hepatic steatosis by imaging or 
histology, (b) there is no significant alcohol consumption, (c) there are no competing etiologies for hepatic 
steatosis, and (d) there are no co‐existing causes for chronic liver disease. 
 
Sonographic and Doppler evaluation 
All patients underwent abdominal sonographic evaluation at baseline and after 6 years. Sonographic 
evaluation was performed after a night fasting. The presence of hepatic steatosis was sonographically 
evaluated. As described by Saverymuttu, the sonographic criterion for the diagnosis of liver steatosis is the 
fall in echo amplitude with depth (rate of posterior beam attenuation), increasing discrepancy of echo 
amplitude between liver and kidney and loss of echoes from thewalls of the portal veins (154). 
 
In our laboratory we developed a sonographic tool for liver steatosis quantification based on the ratio 
between the numeric values of the gray intensity of liver and right kidney evaluated by a computerized 
imaging analysis: the liver/kidney ratio (L/R) (11) This method has 100% sensitivity and specificity in the 
identification of more than 5% liver steatosis (steatosis=L/K>1.26). 
 
The severity of steatosis was therefore sonographically evaluated by the liver/kidney ratio 
(steatosis=L/K>1.26) 
 
We also evaluated the following sonographic and Doppler hepatosplenic parameters: right liver size,spleen 
diameter, portal vein diameter (PV) and flow velocity (PVV), hepatic (PI-L) and splenic arterial pulsatility 
index (PI-S), hepatic vein flow profile and a and s wave velocities. 
 
Biochemical tests: 
 
 
All patients underwent the following biochemical tests at baseline and after 6 years: ferritin, cholesterol, 
triglycerides, AST, ALT, HbA1c, and insulin sensitivity evaluation by the homeostatic model assessment 
( HOMA) test. The HOMA test is a method used to quantify insulin resistance and beta-cell function 
using a mathematical equation: HOMA-IR= fasting plasma glucose x insulin/22.5 (mmol/l). 
Statistical analysis:  
 
 
Results are shown as mean ± SD. Differences among groups were analyzed by Anova and paired and 
unpaired Student's t-test. Statistical significance was set at P < 0.05. 
 
Results: 
 
 
Mean age of evaluated patients at baseline was 638 years, 13 male, 8 female. BMI was 27.31.9. 
 
 
The prevalence of steatosis according to L/K ratio (L/K ratio > 1.26) was 100% at baseline and 80% after 
6 years. 
 
Mean L/K in NAFLD patients decreased from 2.330.53 to 2.020.9 after 6yr (p< 0.001) (Fig 1a). 
BMI was similar after 6 years (26.91.8). 
AST and ALT were reduced (AST: from 26±11 to 20±6 UI/l; ALT from 31±21 to 23±10 UI/l; p<0.05); the 
same was for cholesterol (from 191,5±43,7 to 156±33 mg/dl, p< 0.001) and ferritin (from 209.4±171 to 
117±112 ng/l, p<0.01). No significant changes were found in triglycerides, HbA1c and HOMA test. 
EcoDoppler evaluation: PVV increased from 29.9±5.9 cm/sec to 35.6±6.9 cm/sec (p<0.001); hepatic a wave 
velocity increased from 1.4±11 cm/sec to 6.5±6 cm/sec (p<0.05) while PI-L and PI-S did not change (Fig 1 
a and b). 
 
After 6 years in 6 patients (28%) sonographic steatosis degree worsened while in 15 it improved (Fig 2) 
 
 
We divided patients in two groups: the 6 patients with increased steatosis after 6 years (IS) and the 15 
patients with decreased steatosis (DS), then we evaluated if at baseline IS group had different biohumoral or 
ecoDoppler parameters as compared to DS group in order to identify if there were some parameters useful to 
identify those patients who will increase liver steatosis. (Fig. 2) 
 
The result has been that patients with increased steatosis were those with significantly higher basal values of 
ferritin (297±116 vs 171±140 ng/l, p<0.05) , AST ( 33±16 vs 23±9 UI/l, p<0.05) and, surprisingly, with 
lower PI-L (1.2±0.3 vs 1.9±0.3, p< 0.01).(Fig. 3) 
 
 
 
 
Discussion 
 
Our results seem to confirm that liver steatosis of non-obese type-2 diabetic patients is a benign disease 
which doesn’t worsen with time in the majority of them in absence of any specific treatment. In 20% of 
patients liver steatosis recovered after 6 years. Our echographic finding, based on L/K evaluation, are 
similar to those described by Bertot and Adams based on the review of more than 10 studies with 
histological evaluation of NAFL evolution (22). 
 Also mean values of biochemical tests improved with time: in particular AST, ALT, ferritin and cholesterol. 
 
 
Epidemiological and clinical studies describe frequent association between increased liver fat content and 
transaminases elevation. Transaminases and specifically serum alanine aminotransferase ALT has been 
proposed as a surrogate marker for NAFLD. Nevertheless, only a small proportion of patients with NAFLD 
have elevated serum ALT (155, 156). 
 
In our population mean basal transaminases levels were in the range of normality however the reduction 
after 6 years was statistically significant. Given that serum ALT values within the current “normal” range 
have been associated with NAFLD and a higher risk of cardiometabolic disorders, persons with these 
conditions are included in the apparently healthy sample population that is considered “normal.” Therefore, 
it has been suggested that the upper “normal” limit for serum ALT should be re-evaluated to facilitate the 
identification of individuals with NAFLD (156-158). 
 
Concerning cholesterol levels, extensive dysregulation of cholesterol homeostasis has been documented in 
nonalcoholic fatty liver disease (NAFLD), causing both increased synthesis and uptake of cholesterol as 
well as decreased removal (159) thus, a decrease of serum cholesterol levels reflect an improvement of liver 
metabolism of cholesterol. 
 
Triglycerides levels were not significantly different after 6 years. This data is not in contrast with the finding 
of reduced cholesterol levels because while cholesterol levels are mainly dependent on hepatic methbolic 
function and homeostasis, serum triglycerides are related to adipose tissue (160) and in our study BMI was 
similar after 6 years. 
 
Even if Tarantino et al didn’t find any difference in serum ferritin levels between histologically identified 
NAFL and NASH patients (161), it has been recently demonstrated that ferritin levels are correlated with 
liver stiffness evaluated by transient elastography (162). A serum ferritin >1.5 × ULN was associated with 
hepatic iron deposition, a diagnosis of NASH, and worsened histologic activity and was an independent 
predictor of advanced hepatic fibrosis among patients with NAFLD. Furthermore, elevated SF was 
independently associated with higher NAS, even among patients without hepatic iron deposition (163). 
Thus, the finding of a decrease of ferritin may reflect an improvement of liver fibrosis. 
 
All these results agree with our hepatic hemodynamic finding of a mean increase of PVV. Our findings are 
similar to the studies by Balci (105) and most of the others emphasize the hypothesis that the fatty 
infiltration of the liver causes increased resistance to the flow of portal vein thereby reducing the portal 
blood flow to the liver (105-107). Also the mean increase of A wave can be read as due to an improvement 
of liver steatosis and in particular of adipose related liver stiffness because of the effect of the reduction of 
liver fatty infiltration on hepatic wave retrograde flow due to atrial contraction. It is known that normal 
hepatic venous waveform shows a triphasic pattern and the “triphasic” pattern is due to atrial contraction 
 related retrograde wave, and the loss of A wave leeds to a biphasic (or monophasic) pattern. Loss of tripasic 
pattern in cirrhotics is commonly related to the loss of compliance of liver due to fibrosis (108,.164) 
 
Surprisingly we didn’t  find any difference in HbA1c and HOMA test. HOMA IR has been recently 
demonstrated to be independently associated with the presence of NAFLD in adult diabetic patients and a 
cut-off value of HOMA-IR of 4.5 was proposed as an optimal threshold for discriminating NAFLD from 
non-NAFLD cases (165). 
 
 
In our study basal mean HOMA-IR was 5.2±0.4 and 5.3 ± 0.5 after 6 years. We can hypothesize that in our 
populations insulin resistance was too high to be useful and probably HOMA IR above value of 5 is not 
enough sensitive to reflect an improvement of liver steatosis. 
However the most interesting finding of this study was that patients with increased steatosis after 6 years 
were those with significantly higher basal values of ferritin (297±116 vs 171±140 ng/l, p<0.05) , AST ( 
33±16 vs 23±9 UI/l, p<0.05) and with lower PI-L (1.2±0.3 vs 1.9±0.3, p< 0.01) (Fig 3). 
 
As already discussed, transaminases levels have been proposed as a surrogate marker for NAFLD because 
an increase of serum AST and ALT is related to an increased fat content (156) however transaminase are 
known as a marker of liver injury thus we can hypothesize that increased levels of transaminases are a 
marker of fat related hepatic injury that is not necessary directly related to hepatocytes fat content but to 
hepatocytes fat related damage (58). 
 
Moreover our findings support the idea that AST and ALT upper limits should be reduced in diabetic 
population to better identify patients with higher risk of evolutive steatosis. 
 
Higher ferritin levels could reflect an increased stiffness related to fibrosis as described by (162) but ferritin 
is also a marker of inflammation (166), thus higher levels of ferritin could be related to an inflammatory 
state that can play a pathogenic role in NAFLD worsening. Also in this case large studies are needed to 
identify a reliable cut-off. 
 
The finding of lower PI-L values in patients with “increased steatosis” is more controversial (108) however 
Balasubramanian et al recently reported the same finding and moreover an inverse even not strong inverse 
correlation between PI-L values and liver steatosis (114). 
 
The decrease of PI-L suggests an increased hepatic artery blood flow which could represent the 
compensatory mechanism to a reduced portal flow but patient with increased steatosis had not lower basal 
values of PVV, thus it is hard to explain this hypothesis pathophysiologically by the “buffer theory”. It is 
more likely to hypothesize an imbalance of vasoactive factors related to endothelial dysfunction. 
 Emerging evidence highlighted that increased portal pressure occurs in NAFLD, also in the absence of 
fibrosis, and that both dynamic factors with marked endothelial dysfunction and overproduction of 
vasoactive mediators, and morphological factors with pronounced architectural derangement of sinu- 
soidal anatomy are implicated in its pathogenesis (167, 168). 
 
 
These factors may be involved also in hepatic arterial flow regulation but more specific studies are needed to 
confirm this hypothesis. 
 
In conclusion this study shows that, without any specific treatment, in a follow up of 6 years, liver steatosis 
increases only in less than 1/3 of non-obese diabetic patients and demonstrates that in the majority of them 
sonographic degree of steatosis improves or recovers concurrently with biohumoral parameters. The 
presence of increased levels of serum AST and ferritin and lower PI-L seems to be correlated to a worse 
prognosis and may be used to identify those patients who deserve a higher surveillance. These 
combined biohumoral and Doppler parameters might become important for the prognosis of patients with 
fatty liver but larger studies are needed to identify cutoff value for any of these parameters alone or in 
combination (composite model with a good sensitivity and specificity. 
 
Limits of the study 
 
 
The major limitations of this study are the small number of patients and the lack of liver histology and NAS 
score to confirm the diagnosis of fatty liver and to grade the severity of the condition. However the long 
follow up, even without intermediate  evaluations, offsets this limit and strengthens our observation. 
 EXPERIMENTAL STUDY : EVALUATION OF THE EFFECT OF PPRd ANALOG, L4F and 
EETA IN NAFLD PROGRESSION IN HFD FED RAT 
 
It is very likely that the importance of NAFLD will continue to increase in the future, when the new 
therapies and prevention programs for hepatitis C and B will further reduce the size of viral infections of the 
liver. As previously described, despite the disease severity and prevalence, there are still no approved 
pharmaceutical specific treatments for NAFLD. beyond management of comorbidity and weight loss. 
Unfortunately, weight loss has a poor long-term success rate, which emphasizes the need of alternative 
approaches (28, 88, 116). 
The urgent need for specific drugs which can reverse or prevent the more advanced and clinically relevant 
stages of NAFLD has rendered this a critical area of research. 
Most recent theories (40-44; 50-52, 167) show how innate immune system is involved in NAFLD 
development and progression, and it is likely involved also in the first phases of the disease. As circulating 
monucleate cells (peripheral blood mononucleate cells PBMCs) include circulating monocytes which are 
the circulating precursors of resident macrophages, we assumed that PBMCs “activation” could be 
representative of macrophages/Kupffer cells activation. This idea could led to the development of new non 
invasive blood tests to evaluate NAFLD. In this study we tested the effect of three new potentially usefull 
therapies for NAFLD and we also aimed to evaluate the role of innate immune system in the early phases of 
the disease and the effect  of these drugs on plasmatic citokines and chemokines levels  and PBMCs 
activation. 
 
 
We tested the following drugs: 
 
a) Apolipoprotein A analogue compound: L4F, 
 
 
b) peroxisome proliferator activated receptor delta agonist: PPARdelta agonist 
 
 
c) EET Analog 
 
 
 
 
RATIONALE FOR THE COICE OF THE DRUGS 
 
Apolipoprotein A analogue compound: L4F 
 
L4F is a synthetic ApoA1 analog commercially available. ApoA1 is the major protein component of high 
density lipoproteins. ApoA1 as a component of HDL is involved in fat molecules efflux from cells to target 
organs including back to the liver for excretion. It helps to clear fat (triglycerides and cholesterol) from 
white blood cells within artery walls. Deficiency in apolipoprotein A-I (ApoA-I) sensitizes mice to diet- 
induced obesity, glucose intolerance and NAFLD (169). 
 
Recent studies suggested that patients with non-alcoholic fatty liver disease (NAFLD), including individuals 
with non-alcoholic steatohepatitis (NASH), have smaller HDL particles when compared to individuals 
 without liver pathologies. T he pilot data from this study suggest that changes in the HDL proteome 
may impact the functionality of HDL particles in NAFLD and NASH patients (170) 
 
These proteome changes may alter cardio-protective properties of HDL, potentially contributing to the 
increased cardiovascular disease risk in affected individualsIt thus ApoA1 evaluation is often used as a 
biomarker for prediction of cardiovascular disease. (171, 172). No data are available on the use of this 
compound in NAFLD therapy. 
 
 
 
PPAR delta agonist 
 
PPARs are free fatty acids-activated transcription factors and belong to the nuclear receptor superfamily. 
The 3 PPAR isotypes, PPARα, PPARγ, and PPARδ play a key role in the regulation of lipid and glucose 
metabolism and thazolidinedione are PPARγ agonists (173). 
PPARδ is a ligand-activated transcription factor involved in the regulation of glucose and lipid homeostasis. 
PPARδ is widely expressed and plays a critical role in mitochondrial function, fatty acid oxidation and it has 
been proposed as a therapeutic target for the treatment of metabolic syndrome. Genetic manipulation of PPARδ 
as well as its activation by agonists attenuate dyslipidemia and hyperglycemia, improve whole-body insulin 
sensitivity, and prevent diet-induced obesity. “Long-term activation of PPARδ can improve hepatic steatosis 
by activating fatty acid oxidation in different mouse models (173-175). 
 
PPARδ regulates hepatic expression of very low-density lipoprotein receptor VLDLR and VLDLR plays 
an important role in the development of hepatic steatosis (174). 
 
In humans, 2-week clinical studies in healthy volunteers and moderately overweight subjects demonstrated 
that the synthetic PPARδ agonist GW501516 improves dyslipidemia (reducing plasma triglycerides and 
increasing HDL cholesterol) and glucose metabolism (decreasing plasma insulin), whereas liver fat content 
was reduced (175, 176). 
 
 
 
 
 
EETA analog 
 
Arachidonic acid metabolites, also known as eicosanoids, represent a large biological class of lipids that 
have important activities in maintaining cellular homeostasis. Epoxyeicosatrienoic acids (EETs) are 
arachidonic acid metabolites produced by Cytochrome P450 (CYP450) monooxygenases/epoxygenases 
(177) 
 
EETs exert potent anti-inflammatory properties in the vasculature by inhibiting NF-κB activation in 
endothelial cells (177). Vasodilatory, anti-inflammatory and anti-apoptotic actions of EETs are well 
established. Moreover EETs play a central role in insulin resistance induced endothelial dysfunction. 
 EETs are very important for renal function: renal damage in cardiometabolic syndrome has been attributed, 
at least in part, to impaired eicosanoids metabolism. EET agonists prevent both vascular dysfunction and 
adiposity in vitro and in mice fed high-fat diets (HFD). Moreover EETs seem to be able to modulate insulin 
sensitivity by acting as endogenous ligands of the PPAR family (177, 178). 
 
Liu et al. had recently demonstrated that sEH inhibition could alleviate high-fat diet-induced hepatic 
steatosis, which might involve its anti-inflammatory effect in adipose tissue and direct inhibition in 
liver(179). 
CYP450 system expression and EETs levels are diminished within both the diabetic and obese states, while 
in non-obese diabetic rats epoxide hydrolase, the enzyme responsible for the metabolism of EETs to 
DHETs, is increased (180, 181). DHET has been shown to be involved in lipid metabolism. Both 14,15 EET 
and 14,15 DHET activate and bind to PPAR alpha and gamma which regulate the beta-oxidation of fatty 
acids (182). Though these particular effects of EETs and DHETS are poorly understood, these findings 
suggest that EETs and DHETs play a role in both lipid metabolism and inflammation and therefore may play 
a critical role in signaling processes involved in diabetes and obesity (183). Insulin sensitivity and, thus, 
“healthy adipogenesis”, is mediated by the expression and activation of the PPAR gamma. PPAR gamma 
can be activated by both endogenous and exogenous synthetic ligands such as thiazolidinediones (a drug of 
great importance in diabetes treatment). EETs have been demonstrated to be potential ligands for PPARs 
(184). In diabetic and obese animal models the presence of big and inflammed adipocytes producing TNF 
alfa, MCP-1 and IL6 instead of adiponectin have been described and there is evidence that insulin resistance 
is a consequence of this “pathological” adipogenesis. (185, 186). 
 
Taken together all  these data suggest  a potentially therapeutic role of EETs in NAFLD. EETA is  an 
EET analog that can be solved in the drinking water thus it could be an easily available compound. No data 
are available on its use in dietary model NAFLD. 
 
 
 
DESIGN OF THE STUDY 
 
 
 
We used a rat model of diet induced liver steatosis (High fat diet model) in order to reproduce human 
physiopathology of early phases of NAFLD. 
Thirty male Wistar rats (4-5 weeks old, 150 grams body weight) were purchased from Charles River 
Laboratories. 24 rats have been fed with high fat diet (HFD, 50-60% of calories from fat) for 8 weeks. After 
8 weeks of diet (and a bioptic diagnosis of liver steatosis -more than 5% of fat within hepatocytes- in 3/3 
rats) animals have been divided in 4 groups: 7 untreated (HFD); 7 treated with ApoA1 analog L4F (L4F), 7 
treated with PPARd agonist GW501516, 10 mg/kg every 2 days, intraperitoneally, for 6 weeks (PPARd) and 
3 treated with EET Analog 10 mg/Kg per day in drinking water for 6 weeks (EET). Treatments lasted 6 
weeks. Cardiac and abdominal ecoDoppler evaluation has been performed before treatment and before 
  
 
 
 
 
 
sacrifice. Results have been compared with those obtained from 6 control rats fed with standard diet. 
Histological evaluation of liver steatosis has been performed in all animals at sacrifice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and Methods 
 
All described procedures were conducted in accordance with all institutional and Italian guidelines for 
the care and use of laboratory animals and were approved by the local animal care and use committee 
(CEASA) and by the Italian Ministry of Health. 
 
EcoDoppler Evaluation 
 
 
All animals underwent renal EchoDoppler evaluation and echocardiography performed using the Vevo 
high-resolution in vivo micro-imaging system (VEVO 2100 Visualsonics) at 8 weeks and  before 
sacrifice (14weeks). 
 
Echocardiographic evaluation: transthoracic echocardiography was performed using a 30 Mhz probe. 
Animals were chest shaved and anesthetized with 3% isoflurane, and temperature controlled anesthesia 
was maintained with 1.5% isoflurane. Two-dimensional cine loops and M-mode cine loops of a long- 
axis view and a short-axis view of the LV were recorded. M-mode cine loop of aortic valve was 
recorded and Doppler analysis of LV flow was performed from the long axis B-mode image placing the 
sample volume in the left ventricle, below the mitral annulus. 
 End diastolic area (EDA) and end systolic area (ESA) were measured from the long axis B-mode 
images. Inter ventricular septum (IVS) and left ventricular posterior wall (LVPW) thicknesses, left 
ventricle end systolic and diastolic diameter (LVID) and maximal left ventricular length (LV length) 
were measured in systole and in diastole (s,d) from the long axis and short axis M-mode images, 
according to standard procedures. Cardiac contractility, measured as ejection fraction (EF) were 
determined using the following simplified formula: end diastolic volume (EDV) – end systolic volume 
(ESV)/ EDV (where EDV = (3.14/6)* LVIDd * LVIDd *LV length d and ESV= (3.14/6)* LVIDs * 
LVIDs *LV length s. 
 
Isovolumetric contraction and relaxation times (IVCT, IVRT), and ejection time (ET) were measured 
from transmitral Doppler analysis and myocardial performance index (MPI) was calculated using the 
following formula MPI= IVCT+IVRT/ET. 
 
Hepatic and renal echoDoppler evaluation: immediately after echocardiographic evaluation, abdomens 
of the mice were shaved, renal B-mode cine loops of a transversal section of liver and both kidneys were 
recorded. Color Doppler was used to identify: portal vein, hepatic artery and renal interlobar arteries, 
then Doppler analysis of portal vein flow and identified arteries' flow was performed. Portal vein was 
measured (PV Vel) and arterial Peak Velocity (Vmax), End Diastolic Velocity (Vmin) and Mean 
Velocity (VM) were measured and Pulstility Index (PI) was calculated using the following formula PI= 
(Vmax-Vmin)/Vmean. The mean value of three different measurements was calculated as described. 
Resistive Index (PI) was calculated using the following formula RI= (Vmax-Vmin)/Vmin. The mean 
value of three different measurements was calculated as described (L= liver, for hepatic artery; K= 
kidney, for renal interlobar arteries). 
 
Qualitative assessment of liver steatosis evaluation liver brightness 
 
 
Qualitative assessment of liver steatosis with echographic evaluation is not described in rats, however 
we evaluated the echographic brightness of the liver as compared to right kidney and the operator gave a 
numeric evaluation from 0 to 2 to liver brightness: 0 = less bright than kidney; 1 = mildly less bright 
than kidney; 2 = as bright as kidney. 
 
All rats were imaged by a single operator. 
 
 
Hystological evaluation: 
 
 
At the end of the study rats were euthanized by using carbon dioxide and after sacrifice liver slices were 
fixed in paraformaldehyde for the histological analysis of liver steatosis. 
 
Triglyceride content of rat liver tissue 
 
 
Triglyceride content of rat liver tissue was assessed using a commercially available colorimetric assay 
kit according to manifacturer’s instructions. 
 LAL hepatic levels 
 
 
Lysosomal acid lipase (LAL) in rat liver tissue was evaluated by western blot analysis using specific 
commercially available antibodies.  LAL expression was compared with actin expression. We also 
compared LAL expression to liver triglycerides content and measured the hepatic LAL/triglycerides 
ratio. 
 
Plasmatic cytokines 
 
 
The levels of IL-1β, and CCL2 were determined in serum samples ELISA test according to 
manifacturer’s instructions (eBioscience; Raybiotech). 
 
CCL2 and IL-1 b production in cultured PBMCs 
 
 
PBMCs were isolated from peripheral blood samples by centrifugation and then cultured. PBMCs from 
each rat were dived into two samples:  one sample was cultured without stimuli, the second one 
stimulated with the specific activator of innate immunity receptors lipopolysaccharide (LPS) and the 
inflammatory response (CCL2 and IL1b production) was measured in the supernatant using ELISA kit 
according to manifacturer’s instructions (eBioscience; Raybiotech). 
 
Statistical analysis: the data are presented as mean ± standard error (SEM). For comparison between 
treatment groups, the null hypothesis was tested by unpaired t-test. Statistical significance (p < 0.05) 
between the experimental groups was determined by the Fisher method of analysis for multiple 
comparisons. Correlation between two variables was evaluated with linear regression. 
 
 
 
 
RESULTS 
 
 
Effects of HFD on liver triglycerides content and LAL expression, cardiac and abdominal 
ecoDoppler evaluation and cytokines production. 
 
100% of rats fed with HFD developed obesity and mild liver steatosis (Fig 4). In 60% of animals liver 
steatosis was microvescicular, without fibrosis and without inflammatory infiltration (Fig 5). Liver 
content of triglycerides: 16±4 mmol/g protein vs 5±1 mmol/g protein of CTR (Fig 5). Liver steatosis 
was associated with a significant reduction of portal vein velocity (PV vel) as compared to CTR 
(173±40 vs 354±87 mm/sec p<0.05) (Tab 1). Portal vein velocity was inversly correlated with liver 
steatosis (Fig 6a). No rats fed with standard diet developed steatosis. No significant differences were 
noticed in hepatic arterial resistance but hepatic artery resistance had a direct correlation with liver 
steatosis (Fig 6b). Renal resistances (K- RI) were significantly increased as compared to control rats 
(0.63±0.03 HFD vs 0.55±0.02 CTR, p<0.01). 
 
Liver brightness in HFD rats was 2 in all animals and 0 in all CTRs. 
 Rats fed with HFD developed a significant cardiac diastolic dysfunction (Myocardial Performance Index 
 
-MPI- 0.92±0.1 vs 0.76 ±0.1 of CTR; p<0.05). 
 
 
Hepatic LAL expression was increased in HFD group (Fig 7) but LAL/triglycerides ratio was 
significantly reduced (Fig 8). 
 
Plasma levels of CCL2 were significantly increased in HFD rats (Fig 10) while IL1 β was not detectable 
(data not shown). PBMCs isolated from HFD showed only a minimum increase in CCL2 production but 
the stimulation with LPS increased an average of 5 fold its production (the average increase in LPS 
stimulated CTR PBMCs was less than 2 fold) (Fig 11 a and b). Il1 β was produced only by stimulated 
PBMC isolated from HFD rats. (Fig 9). 
 
 
 
 
Effect of L4F 
 
 
Treatment with L4F reduced the percentage of rats with steatosis  (72% of animals) and medium 
triglycerides liver content (11±2 mmol/g protein, p< 0.05 vs HFD) (Fig 5) and improved PV velocity 
(326 ± 80 mm/sec; p<0.05 vs HFD) although body weight was not different from HFD group (Tab 1). 
Only 25% of L4F treated steatosic rats had microvescicular steatosis (Fig 5). 
 
Hepatic and renal arterial resistances were no significantly different from HFD group, the same was for 
MPI although its value was lower than HFD rats and not significantly different from CTR rats. 
 
Liver brightness: L4F=0,58 (p<0.01 vs HFD) 
 
 
Hepatic LAL expression was reduced but not significantly different from HFD rat, the same was for 
LAL/triglycerides ratio (Fig 7, 8). 
 
Plasma levels of CCL2 were similar to those of CTR rats and IL1 β was not detectable. Isolated PBMCs 
showed a significantly reduced production of CCL2 in basal conditions and also after LPS stimulation 
(Fig 11) even if the average increase after LPS stimulation was only 3 fold (Fig 11 b). 
 
 
 
 
Effect of PPARδ agonist 
 
 
Treatment with PPARδ reduced hepatic mean content of triglycerides (9±2 mmol/g protein, p< 0.05 vs 
HFD) (Fig 5) even if 100% still had histologically detectable liver steatosis after treatment. 28% of 
PPARδ treated steatosic rats had microvescicular steatosis. Body weight was similar to HFD rats. 
 
PV velocity was increased as compared to HFD rats (260±86 mm/sec; p<0.05 vs HFD) but significantly 
reduced as compared to CTR rats (Tab 1). 
 Hepatic and renal arterial resistances were not different from HFD group, the same was for MPI 
although its value was lower than HFD rats and no significantly different from CTR rats (Tab 1). 
 
Liver brightness: PPAR delta 0.78 (p<0.01 vs CTR e vs HFD) 
 
 
Hepatic LAL expression was reduced as compared to HFD while LAL/triglycerides ratio was increased 
even not significantly (Fig 7, 8). 
 
Plasma levels of CCL2 were similar to those of CTR rats and IL1 β was not detectable. Isolated PBMCs 
showed a significantly reduced production of CCL2 in basal conditions and also after LPS stimulation 
(Fig 11) 
 
 
 
 
Effect of EET A 
 
 
All EET analog treated rats developed microvescicular steatosis and triglycerides levels were similar to 
those of untreated rats (16±4 mmol/g protein, p<0.05 vs CTR) (Fig 5). PV velocity was lower as 
compared to HFD rats (114±17 mm/sec; p< 0.05 vs HFD). Body weight was not significantly higher 
than CTR rats (non obese phenotype) Tab 1). 
 
MPI was similar to HFD rats and left ventricle diastolic volume was increased as compared to HFD rats 
(tab 1). 
 
No differences were observed in arterial resistances although hepatic artery RI and PI were similar to 
those of CTR mice and lower than HFD, PPARd and L4F rats. 
 
Liver brightness: EETA=1,85 (p<0.01 vs CTR). 
 
 
Hepatic LAL expression was reduced but not significantly different from HFD rat while 
LAL/triglycerides was significantly lower than HFD group (Fig 7,8). 
 
Plasma levels of CCL2 were higher as compared to those of CTR rats but lower than those of HFD rats. 
IL1 β was not detectable. Isolated PBMCs showed a significantly reduced production of CCL2 in basal 
conditions and LPS stimulation increased CCL2 expression less than 2 fold as in CTR mice (Fig11). 
 
 
 
 
DISCUSSION 
 
 
Characterization of the model: 
 
 
This is the first study which characterized the sonographic and hemodynamic alterations of HFD induced 
NAFLD in rats. Our study shows that HFD related liver steatosis in rat obese-IR phenotype (136) is 
associated to a systemic activation of innate immunity (increase in plasmatic CCL2 levels) and enhanced 
 response to pro-inflammatory stimuli such as LPS (increase in plasmatic IL1 β levels). The role of the 
activation of innate immune system is well described in steatohepatitis (187, 188). 
 
Interestingly in this study we demonstrate that the activation of innate immunity is present even in the 
absence of liver inflammatory infiltration and fibrosis. This observation is in line with some recent 
studies which demonstrated that lipids are able to regulate immune cells activation and macrophages 
phenotype (189). 
 
Altered lipid homeostasis underlies the etiology of some of the most common chronic diseases — 
obesity, cardiovascular disease (CVD) and liver disease. In 2007, Lumeng et al. (190). demonstrated that 
in lean adipose tissue macrophages display an M2 phenotype while there are more M1 macrophages 
under obese condition. One explanation is that saturated fatty acids can bind TLRs to activate NFκB 
pathways, inducing the up-regulation of CCL2, IL-1β and TNF-α. Scavenging activity by macrophages 
can lead to the intracellular accumulation of saturated fatty acids (SFAs) and other lipids such as 
diacylglycerols (DAGs). The accumulation of SFAs and DAGs can be toxic by inducing endoplasmic 
reticulum stress, which also drives the inflammatory M1 phenotype in macrophages (191). Monocyte- 
derived macrophages are the primary immune cell to accumulate in atherosclerotic plaques (192, 193). 
 
 
PBMCs are representative of circulating monocytes that are precursor of resident macrophages and in 
this study we demonstrate that in HFD fed animals PBMCs are involved in CCL2 increased production 
and moreover PBMCs are significantly more sensitive to LPS stimulation (further increase of CCL2 
production: 5 fold as compared to less than 2 fold in CTR). Thus HFD induce a “hyper reactive” state in 
PBMCs. 
 
As resident macrophages and Kupffer cells are sensitive to the same mechanisms, we can hypothesize a 
similar activation of Kupffer cells. Kupfer cells activation is involved in liver steatosis development as 
proposed by Hubler et al who described how molecular pathways driven by lipid accumulation tend to 
promote a proinflammatory cellular phenotype in immune cells (194) 
 
Moreover, it has been described that LPS activated PBMCs can activate HSC and promote liver fibrosis 
(195). Thus, a pro inflammatory state of PBMCs can be considered a predisposition to liver fibrosis. 
 
Concerning splanchnic hemodynamics alterations, this rat model amplifies what happens in humans: we 
found a significant reduction of PVV even in mild degrees of liver steatosis (104-107). 
 
Despite normal cardiac systolic function and normal LV wall thicknesses, HFD rats showed a significant 
diastolic disfunction (increased MPI) and this is what is described also in the obese phenotype (196). 
Unfortunately, we lack the values of blood pressure but hypertension is described in HFD rat models 
(144, 145) and the idea that these rats were probably hypertensive is supported by the finding of 
increased K- RI. 
 Contrary to what was described by Baratta (84) in this rat model of NAFLD we found a significantly 
increased hepatic LAL activity; however the LAL/triglycerides ratio was reduced as compared to control 
rats. The increase in liver triglycerides content seems to induce LAL activity but not enough to be 
adequate to the increase of lipids. Thus, the effect is a relative deficiency of LAL. LAL expression in 
this model is the physiological consequence of the increased lipid influx in cells as the autophagy of 
lipid droplets is the cellular response to decreased lipids content. As described by Ouimet et al for 
macrophage foam cells (197), LAL activity is functional to destroy cellular lipid droplets, thus a relative 
deficiency results in the intracellular accumulation lipids. 
 
 
 
 
Effects of the treatments: 
 
 
L4F and PPARd improved liver steatosis and reduced plasma and PBMCs derived CCL2 production. 
Both treatments have a “metabolic effect”, the first one particularly on lipid metabolism and HDL 
related cholesterol flux (169-172) the second on FFAs activated transcriptional pathways protecting cells 
from cholesterol overload with a particular effect on VLDL related cholesterol flux (173-176). 
 
Both treatments improved liver steatosis that was mainly macrovescicular and portal vein velocity that 
was higher as compared to HFD untreated mice. Portal vein velocity was correlated with the percentage 
of liver steatosis. 
 
Their effect on liver triglycerides content is easily comprehensible and, as portal vein velocity, was 
related to liver fat content (104-107). Also the improvement of portal vein velocity has a direct 
explication. Less immediate is the understanding of their effect on CCL2 production. While PPARd 
agonist, as a transcriptional activator, may cause the activation of anti-inflammatory molecular pathways 
with a reduction of chemokine and cytokine production (173, 176, 198), L4F should have an effect only 
on cholesterol flux. These data support the idea that immune system activation is strictly related to lipid 
metabolism (189, 194) thus, improving lipid metabolism reduces the lipid related pro-inflammatory 
activation of PBMCs. 
 
However these argumentations let infer that the improvement of liver steatosis is the hepatic effect of the 
systemic improvement of lipid metabolism and immune system activation, except that we observed a 
clear change in liver steatosis histology: while in HFD group liver steatosis was microvescicular in 60% 
of animals, in PPARd and L4F groups it was microvescicular respectively 30% and 25% of animals and, 
(27) as described by Fromenty et al, microvescicular steatosis is related to mithochondrial dysfunction 
and impaired lipids beta-oxidation- (25, 26). Impaired beta oxidation is a pathogenetic characteristic of 
liver steatosis and as recently reported by Kim et al the improvement of hepatic steatosis by novel 
PPARalfa agonist  is  due  to  its  effect  on  the  improvement  of  hepatic beta  oxidation (199).  The  
effect  on  this  histological feature is a specific hepatic effect of these drugs and is probably related to 
the pro inflammatory state of hepatocytes environment due to Kupffer cells activation. 
  
An interesting observation is that both PPARd and L4F reduced CCL2 production in PBMCs but 
preserved the ability of PBMCs to react to LPS stimulation (average 3 fold increase of CCL2 production 
after LPS stimulation, Fig 11), this is the main difference of these two treatments as compared to EETA 
effect. In EETA treated rats LPS stimulation didn’t increased CCL2 production. This observation 
sustains the idea that an excessive immunosuppressive effect is not beneficial for liver steatosis as 
described in some studies about de-novo NAFLD occurrence after liver transplantation in which 
tacrolimus and steroids are described as causative element of NAFLD development (200, 201) 
 
The unexpected finding of this study was the effect of EETA compound. As described by Spector AA 
(177) in HFD mice, also in our HFD fed rats the EET agonists reduced adiposity (significant decrease of 
body weight) and, as widely described (186), EETA exerted an anti-inflammatory effect on PBMCs 
but didn’t improve liver steatosis that histologically was microvescicular in 100% of animals. 
 
Even though the systemic anti-inflammatory activity of this compound was expected (186), the specific 
reduction of PBMCs related CCL2 production and the reduced response of PBMCS to LPS stimulation 
is a new finding. A specific relationship between EETs and CCL2 production has already been described 
by Kundu et al. who demonstrated that sEH inhibition blocks monocyte chemotaxis and particulary sEH 
derived products, dihydroxyeicosatrienoic acids (DHETs), are able to restore CCL2 dependent 
chemotaxis, concluding that DHETEs are involved in CCL2 dependent chemotaxis (202). Taken 
together with our finding we can speculate that probably it is the balance between EETs and DHETs that 
is involved in CCL2 dependent chemotaxis. 
 
Concerning splanchnic hemodynamics, EETA further decreased portal vein velocity and we found also a 
decrease of L-PI. This finding reproduces what is described in clinical studies (104-107) in which the 
decrease of liver PI suggests an increased hepatic artery blood flow which could represent the 
compensatory mechanism to a reduced portal flow even if, as the well described effect of EETs as 
vasoactive compounds (186), it is more likely to hypothesize an imbalance of vasoactive factors related 
to endothelial dysfunction. We have previously shown how EETs, which are potent arterial vasodilators, 
cause vasonstriction in the portal circulation (203) 
 
Recently Pereira et al described hepatic microvascular dysfunction as a component of non-alcoholic fatty 
liver disease (204). Thus, the reduced hepatic arterial resistance in EETA treated rats could cause an 
increase in sinusoidal permeability, and an increased sinusoidal permeability could be one pathogenetic 
element of NAFLD. 
 Many recent papers sustain the idea that the gut microbiota might control the severity of NAFLD by 
increasing production of ethanol, activating TLR signaling and TNF production in the liver, or altering 
the bile acid profile (205-207) 
 
An increased sinusoidal permeability (but even intestinal as EETA compound was administered by 
drinking water and should have a systemic effect) increases the flux of bowel derived substances to the 
liver and this, in conjunction with the “immunosuppressive” effect of the compound could explain the 
worsening of liver steatosis in HFD fed and EETA treated rats. 
 
 
 
 
 
 
CONCLUSIONS 
 
 
Wistar rat model of HFD induced NAFLD reproduces splanchnic haemodynamic alteration of liver 
steatosis in humans and shows an activation of innate immune system also at early degree of steatosis 
without hepatic inflammation and fibrosis. The activation of innate immune system can be evaluated by 
the analysis of LPS stimulated/unstimulated CCL2 production in cultured PBMCs. 
 
PPARd agonist and L4F improved HFD induced liver steatosis and reduced CCL2 production in PBMCs 
but preserved the ability of PBMCs to react to LPS stimulation 
 
EETA administration didn’t improved liver steatosis and further decreased portal vein velocity and 
reduced the ability of PBMCs to react to LPS stimulation. 
 
On the basis of these results we recently got the Ministerial approval for an extended study to better 
understand the effect of EETs related compound on HFD fed mice. 
 
Limits of the study 
 
We chose this rat model of NAFLD because we aimed at reproducing the pathophysiology of NASH. 
HFD fed rats are perhaps the best model of this disease because of mild progression to NASH as 
described in epidemiological studies. However, to clarify the real role of innate immune system in 
NAFLD, a specific innate immune system targeted model may be needed. Unfortunately, even a 
selective innate immune deficient mice model is not simple to establish. Probably, the best way to 
improve and demonstrate our hypothesis is in in-vitro models of cellular interaction such as a 
cocolture of fatty liver derived Kupffer cells and/or PBMCs and healthy hepatocytes and vice versa. 
We need to identify the molecular pathway of interaction between innate immune system and liver. 
Further studies which look into the exact pathophysiology of the described haemodynamic changes are 
also needed. 
 TABLE 1: EcoDoppler evaluation of cardiac and abdominal parameters; body weigt at sacrifice. 
 
 
CTR HFD L4F PPARd EET 
 
LV Vol d (ul) 295 ±75 242± 24 261 ±58 273±67 312 ± 23^ 
 
EF (%) 74 ±10 81±6 72 ±10 78± 8 72± 9 
 
MPI 0.76 ±0.1§ 0.92±0.1* 0.86 ±0.2 0.85 ±0.2 0.91 ±0.2 
 
PV d (mm) 1.8 ±0.3 1.8 ±0.1 1.9 ±0.4 1.9± 0.4 2.2 ±0.4 
 
PV vel (mm/sec) 354±87§§ 173±40 ** 326 ± 80§§ 260±86§* 114±17§** 
 
L RI 0.58 ±0.07 0.64 ±0.06 0.65 ±0.1 0.66± 0.1 0.60± 0.08 
 
K RI 0.55±0.0 0.63±0.03* 0.55± 0.08 0.59 ±0.03 0.59 ±0.03 
 
Liver Brightness 0 2** 0.58§§ 0.75§§** 1.83** 
 
Body weight (g) 530±60 690±70* 650±60* 670±50* 640±90 
 
 
 
 
 
 
LV Vol d: left ventricle diastolic volume; EF : ejection fraction; MPI: Myocardial Performance Index; PVd: 
portal vein diameter; PV vel portal vein velocity; L RI:liver resistance index (hepatic artery); K RI: kidney 
resi stance index * p < 0.05 vs CTR; ** p < 0.01 vs CTR; §p < 0.05 vs HFD; §§ p < 0.01 vs HFD 
 FIGURES 
 
CLINICAL STUDY: 
 
Figure 1 a: mean values of EchoDoppler measurements at baseline and after 6 years. 
Figure 1 b: mean values of biochemical tests at baseline and after 6 years 
Figure 2: graphic representation of L/K ratio variation in each patient at baseline and after 6 years. Each line 
represent a single patient. In red patients in which liver steatosis was increased after 6 years, in light blue 
patients in which liver steatosis was reduced after 6 years (according to the sonographic evaluation of L/K) 
 
Figure 3: mean values of the parameters that were significantly different at basal evaluation in those patients 
with an increased steatosis after 6 years: ferritin (a) (increased, p<0.005), aspartate-aminotransferase- AST- 
(b) (increased, p< 0.05) and liver pulsatility index- PI-L (c) (decreased, p<0.01). 
EXPERIMENTAL STUDY: 
Figure 4: a) macroscopic aspect of the liver at sacrifice in one rat of the HFD group. B) liver histology of a 
control rat. c) liver histology of high fat diet fed rat: in this animal liver steatosis was mainly 
macrovescicular. No signs of inflammatory infiltrate or liver fibrosis were present. 
 
Figure 5: Liver triglycerides content express as mmol of triglycerides / gram protein in homogenized liver 
samples (method: colorimetric assay). In blue the percentage of animals with mainly microvescicular 
steatosis for each group. p < 0.05 vs CTR; ** p<0.01 vs CTR; §p < 0.05 s HFD; § § p<0.01 vs HFD; 
 
Figure 6: a) correlation between portal vein velocity (PV Vel) and percentage of liver steatosis; b) 
correlation between hepatic artery pulsatility index and percentage of liver steatosis. 
 
Figure 7: hepatic expression of LAL (a) evaluated by Western Blot (b) * p < 0.05 vs CTR; §p < 0.05 s 
HFD. 
 
Figure 8: hepatic expression of LAL compared to liver triglycerides content. * p < 0.05 vs CTR; § p < 0.05 s 
HFD. 
 
Figure 9: Production of IL1 β by LPS stimulated PBMCs: IL1 β production was relievable only HFD 
group. 
 
Figure 10: plasmatic levels of CCL2. Blood samples were collected at sacrifice and CCL2 levels were 
evaluated by ELISA test.  * p < 0.05 vs CTR. 
 
Figure 11: a) CCL2 production in cultured PBMCs with (black) and without (brown) LPS stimulation. b) 
graphic representation of CCL2 fold increase after LPS stimulation: CCL2 in LPS stimulated PBMCs/CCL2 
in unstimulated PBMCs. 
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